Council for Innovation Promotion

Last week, C4IP board members and former federal judges Paul Michel and Kathleen O’Malley published an opinion piece in The Hill highlighting the dire need to pass the Patent Eligibility Restoration Act. The piece traces the origins of the current “crisis of patentability” back to a pair of Supreme Court cases in the early 2010s.

This month, C4IP is recognizing Mark Dean, a pioneer of personal computers. Dean was born in Jefferson City, Tennessee, in 1957, and studied electrical engineering at the University of Tennessee and Florida Atlantic University before becoming chief engineer of IBM’s personal computers division at the age of 25. He led the team behind IBM’s first personal computer and holds three of

Innovation requires IP. Without a strong patent system, innovation does not happen at scale. Virtually every invention of impact is patented, as exemplified by these historical examples from the month of February: 1916: On February 8, Charles Kettering received a patent for the first self-starting automobile engine, a technology that has since been universally incorporated

February was a busy month for C4IP! Here’s a roundup of what our Coalition accomplished over the past month. February Highlights: Protecting the Bayh-Dole Act February 6 concluded NIST’s public comment period for the newly proposed “march-in” framework, which would twist the Bayh-Dole Act into a mechanism for government price control. If implemented, such government

Former USPTO Director and C4IP Co-Chair David Kappos published an opinion piece this week in the Brussels Times advocating against the European Parliament’s proposal to micromanage standard-essential patent (SEP) licensing, which would represent a massive blow to European tech innovators if adopted. Kappos explains how the European Parliament’s proposal, which would task bureaucrats with managing

Claim: During a January 23 Senate Judiciary Subcommittee on Intellectual Property hearing, Richard Blaylock — on behalf of Invitae Corporation — claimed that “PERA as introduced would stifle innovation and harm patient care in the fields of diagnostic genetic testing and precision medicine.” Correction: The Patent Eligibility Restoration Act (PERA) is an essential reform to